Alectinib (ALECENSA) is THE ONLY preferred first-line treatment option (Category 1) for ALK+ metastatic NSCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 4*
*When an ALK rearrangement is discovered prior to first-line systemic therapy.
1L PFS Results
View PFS results vs crizotinib from the head-to-head ALEX
Dosing and Administration
Learn about dosing and monitoring for ALECENSA.
Financial Support for Patients
Learn more about ALECENSA patient and practice resources.